WHAT IS KNOWN AND OBJECTIVE: Anidulafugin is an echinocandin used for the treatment of candida infections in non-neutropenic adults. Echinocandins show few drug-drug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration. CASE SUMMARY: A 41-year-old man ICU patient received anidulafungin for a suspected Candida glabrata infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability. WHAT IS NEW AND CONCLUSION: To the authors' knowledge, this is the first report of a life-threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.
WHAT IS KNOWN AND OBJECTIVE: Anidulafugin is an echinocandin used for the treatment of candida infections in non-neutropenic adults. Echinocandins show few drug-drug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration. CASE SUMMARY: A 41-year-old man ICU patient received anidulafungin for a suspected Candida glabrata infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability. WHAT IS NEW AND CONCLUSION: To the authors' knowledge, this is the first report of a life-threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.
Authors: C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2015-09 Impact factor: 1.041
Authors: Christian Koch; Emmanuel Schneck; Christoph Arens; Melanie Markmann; Michael Sander; Michael Henrich; Markus A Weigand; Christoph Lichtenstern Journal: Int J Clin Pharm Date: 2019-11-21
Authors: Christian Koch; Jennifer Jersch; Emmanuel Schneck; Fabian Edinger; Hagen Maxeiner; Florian Uhle; Markus A Weigand; Melanie Markmann; Michael Sander; Michael Henrich Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Christian Koch; Florian Uhle; Matthias Wolff; Christoph Arens; Astrid Schulte; Ling Li; Bernd Niemann; Michael Henrich; Susanne Rohrbach; Markus A Weigand; Christoph Lichtenstern Journal: Antimicrob Agents Chemother Date: 2014-12-29 Impact factor: 5.191
Authors: Tobias Lahmer; Christopher Schnappauf; Marlena Messer; Sebastian Rasch; Lisa Fekecs; Analena Beitz; Stefan Eser; Roland M Schmid; Wolfgang Huber Journal: Infection Date: 2015-08-11 Impact factor: 3.553
Authors: Christian Koch; Matthias Wolff; Michael Henrich; Markus A Weigand; Christoph Lichtenstern; Florian Uhle Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: C Arens; F Uhle; M Wolff; R Röhrig; C Koch; A Schulte; S Weiterer; M Henrich; M A Weigand; K-D Schlüter; C Lichtenstern Journal: Anaesthesist Date: 2014-02-07 Impact factor: 1.041